BACKGROUND:According to the World Health Organization, approximately 15% of the global population is affected by mental health or substance use disorders. These conditions contribute significantly to the global disease burden, which has worsened because of the direct and indirect effects of COVID-19. In Mexico, a quarter of the population between the ages of 18 and 65 years who reside in urban areas present a mental health condition. The presence of a mental or substance abuse disorder is behind a significant percentage of suicidal behaviors in Mexico, where only 1 in 5 of those who have these disorders receive any treatment.OBJECTIVE:This study aims to develop, deploy, and evaluate a computational platform to support the early detection and intervention of mental and substance use disorders in secondary and high schools as well as primary care units. The platform also aims to facilitate monitoring, treatment, and epidemiological surveillance ultimately helping specialized health units at the secondary level of care.METHODS:The development and evaluation of the proposed computational platform will run during 3 stages. In stage 1, the identification of the functional and user requirements and the implementation of the modules to support the screening, follow-up, treatment, and epidemiological surveillance will be performed. In stage 2, the initial deployment of the screening module will be carried out in a set of secondary and high schools, as well as the deployment of the modules to support the follow-up, treatment, and epidemiological surveillance processes in primary and secondary care health units. In parallel, during stage 2, patient applications to support early interventions and continuous monitoring will also be developed. Finally, during stage 3, the deployment of the complete platform will be performed jointly with a quantitative and qualitative evaluation.RESULTS:The screening process has started, and 6 schools have been currently enrolled. As of February 2023, a total of 1501 students have undergone screening, and the referral of those students presenting a risk in mental health or substance use to primary care units has also started. The development, deployment, and evaluation of all the modules of the proposed platform are expected to be completed by late 2024.CONCLUSIONS:The expected results of this study are to impact a better integration between the different levels of health care, from early detection to follow-up and epidemiological surveillance of mental and substance use disorders contributing to reducing the gap in the attention to these problems in the community.INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID):DERR1-10.2196/44607.
In the experiment of albino rats it was shown that hypobaric hypoxia caused a disorders of hemostasis with destabilization of membranes and imbalance of electrolytes in the erythrocyte-plasma-vessel wall system. Streptase administration in a dose of 2500 U/kg in this case events in some degree the changes in the process of the blood coagulation, viscosity-elasticity properties of erythrocytes, calcium levels in plasma and erythrocytes, sodium and magnium levels in the abdominal aorta wall produced by the "altitude rise" in an altitude chamber.
On the 3rd day after the last administration of phenobarbital (50 mg/kg orally, 4 days), benzonal (35 mg/kg orally, 4 days), zixorine (200 mg/kg orally, 4 days) and 3-methylcholanthrene (20 mg/kg subcutaneously, 2 days) the rats exhibited a decrease of iodamide secretion in the kidneys. The administration of zixorine to the dog (200 mg orally, 6 days) led to a significant decrease of iodamide transport in the first two weeks after discontinuation of the drug administration.
Gentamicin distribution in some tissues of the abdominal cavity one hour after the intralymphovasal and intranodular administration to 32 rabbits was studied. The experiments were performed under conditions of the blocking and external drainage of the thoracic lymphatic duct. It was found that the optimal bacteriostatic concentrations were reached at both intralymphovasal and intranodular administration.
